

**CENTER FOR DRUG EVALUATION AND RESEARCH**

**Approval Package for:**

***APPLICATION NUMBER:***

**202895Orig1s000**

***Trade Name:*** Prezista suspension, 100 mg/mL and tablets,  
75 mg, 150 mg, 400 mg, and 600 mg.

***Generic Name:*** darunavir

***Sponsor:*** Tibotec, Inc

***Approval Date:*** December 16, 2011

***Indications:*** Prezista® (darunavir) oral suspension in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 3 years of age and older and weighing at least 10 kg.

# CENTER FOR DRUG EVALUATION AND RESEARCH

## 202895Orig1s000

### CONTENTS

#### Reviews / Information Included in this NDA Review.

<b>Approval Letter</b>	<b>X</b>
<b>Other Action Letters</b>	
<b>Labeling</b>	<b>X</b>
<b>REMS</b>	
<b>Summary Review</b>	<b>X</b>
<b>Officer/Employee List</b>	<b>X</b>
<b>Office Director Memo</b>	
<b>Cross Discipline Team Leader Review</b>	
<b>Medical Review(s)</b>	<b>X</b>
<b>Chemistry Review(s)</b>	<b>X</b>
<b>Environmental Assessment</b>	
<b>Pharmacology Review(s)</b>	<b>X</b>
<b>Statistical Review(s)</b>	
<b>Microbiology Review(s)</b>	<b>X</b>
<b>Clinical Pharmacology/Biopharmaceutics Review(s)</b>	<b>X</b>
<b>Other Reviews</b>	<b>X</b>
<b>Risk Assessment and Risk Mitigation Review(s)</b>	
<b>Proprietary Name Review(s)</b>	
<b>Administrative/Correspondence Document(s)</b>	<b>X</b>

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**202895Orig1s000**

**APPROVAL LETTER**



NDA 202895  
NDA 21976/S-020

**NDA APPROVAL**  
**NDA SUPPLEMENT APPROVAL**

Tibotec, Inc  
Attention: Charles Zezza, Ph.D., M.B.A.  
Director, Global Regulatory Affairs  
920 Route US Highway 202S  
PO Box 300  
Raritan, NJ 08869

Dear Dr. Zezza:

Please refer to your New Drug Application (NDA) dated March 29, 2011 received March 30, 2011 and your supplemental NDA dated and received June 28, 2011 submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Prezista<sup>®</sup> (darunavir) suspension, 100 mg/mL and tablets, 75 mg, 150 mg, 400 mg, and 600 mg.

We acknowledge receipt of your amendments dated:

March 29, 2011	June 30, 2011	September 9, 2011
April 13, 2011	July 7, 2011	September 12, 2011
April 19, 2011	July 13, 2011	September 14, 2011
April 26, 2011	July 19, 2011	September 21, 2011
April 28, 2011	July 28, 2011	September 22, 2011
May 3, 2011	July 29, 2011	September 23, 2011
May 9, 2011	August 4, 2011	September 28, 2011
June 2, 2011	August 10, 2011	November 9, 2011
June 7, 2011	August 12, 2011	November 30, 2011
June 9, 2011	August 18, 2011	December 12, 2011
June 10, 2011	August 19, 2011	December 15, 2011
June 15, 2011	August 22, 2011	December 16, 2011
June 23, 2011	September 1, 2011	
June 28, 2011	September 8, 2011	

The NDA provides for the use of Prezista<sup>®</sup> (darunavir) oral suspension in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 3 years of age and older and weighing at least 10 kg.

The supplemental NDA updates the Prezista<sup>®</sup> (darunavir) oral tablets labeling within information related to the oral suspension formulation.

We have completed our review of these applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling text for the package insert and patient package insert. Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **CARTON AND IMMEDIATE CONTAINER LABELS**

For NDA 202895, submit final printed carton and container labels that are identical to the enclosed carton and immediate container labels as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry titled “Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008).” Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “**Final Printed Carton and Container Labels for approved NDA 202895.**” Approval of this submission by FDA is not required before the labeling is used.

Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

### **MARKET PACKAGE**

Please submit one market package of the drug product when it is available.

If sending via USPS, please send to:

Linda C. Onaga, MPH  
Food and Drug Administration  
Center for Drug Evaluation and  
Research  
White Oak Building 22, Room: 6321  
10903 New Hampshire Avenue  
Silver Spring, Maryland 20993

If sending via any carrier other than USPS  
(e.g., UPS, DHL), please send to:

Linda C. Onaga, MPH  
Food and Drug Administration  
Center for Drug Evaluation and  
Research  
White Oak Building 22, Room: 6321  
10903 New Hampshire Avenue  
Silver Spring, Maryland 20903

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for ages 0 to 3 years because there is evidence strongly suggesting that the drug product would be unsafe in this pediatric group. This decision is based on the results of juvenile rat toxicology studies that provide evidence of a potential safety risk as a result of drug-brain accumulation.

This product is appropriately labeled for use in ages 6 to 17 years for this indication. Therefore, no additional studies are needed in this pediatric group.

We note that you have fulfilled the pediatric study requirement for ages 3 to 6 years for this application.

### **POSTMARKETING COMMITMENTS NOT SUBJECT TO THE REPORTING REQUIREMENTS UNDER SECTION 506B**

We remind you of your postmarketing commitment for NDA 202895:

- 1816-1 Collect dissolution profile data from all full-scale batches manufactured during the first year after approval date. The collection of the dissolution data will target the dissolution specifications recommended by the FDA and will include dissolution testing at Stage 1, 2, or 3 as appropriate. Submit the final dissolution report with complete dissolution information/data, a proposal for final dissolution specifications, and data analysis with the number/percentage of batches tested at Stage 1, 2, or 3 or which failed the dissolution specifications recommended by FDA.

The timetable you submitted on September 9, 2011 states that you will conduct this study according to the following schedule:

Study Completion:	12/2012
Final Report Submission:	03/2013

Submit chemistry, manufacturing, and controls protocols and all study final reports to this NDA. In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii) you should include a status summary of each commitment in your annual report to this NDA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies/trials, number of patients entered into each study/trial. All submissions, including supplements, relating to these postmarketing commitments should be prominently labeled “**Postmarketing Commitment Protocol,**” “**Postmarketing Commitment Final Report,**” or “**Postmarketing Commitment Correspondence.**”

### **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Drug Marketing, Advertising, and Communications  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Linda C. Onaga, MPH, Regulatory Project Manager, at (301) 796-0759.

Sincerely,

*{See appended electronic signature page}*

Debra Birnkrant, M.D.  
Director  
Division of Antiviral Products  
Office of Antimicrobial Products  
Center for Drug Evaluation and Research

ENCLOSURE(S):

Content of Labeling  
Carton and Container Label

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

JEFFREY S MURRAY  
12/16/2011